Pricing

Inhibrx, Inc (INBX)

followers ·
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO: Mark P. Lappe
Employees: 110
Web site: inhibrx.com
11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA, CA, 92037
(858) 795-4220

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Are you looking for this stock instead?

All 13F Filers Prior Change Hedge Funds 1 Prior Change
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available